Clinical trials: Female Sexual Dysfunction
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- EDELWEISS 5 (NCT04372121)
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03986944
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 112 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Stress Urinary Incontinence, Sexual Dysfunction
Effectiveness of Kegel Exercise Device in Strengthening Pelvic Floor and Treating Urinary Incontinence (UI)
This study will assess the effectiveness of a new pelvic floor exercise device in strengthening pelvic floor muscles and treating urinary incontinence among women who are experiencing symptoms of pelvic floor weakness.
- Trial name
- NCT02617472
- Testing
- Pelvic floor exerciser
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Lelo Inc.
Premature Ejaculation
A Safety and Tolerability Study of Administration of PSD502
A Phase I, Single-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Pharmacokinetic and Safety Study to Evaluate Systemic Exposure and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites 2,6…
- Trial name
- NCT01183208
- Testing
- Intervention A, Intervention B, Intervention C
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Plethora Solutions Ltd
Vulvovaginal Atrophy, Urinary Incontinence
Combination of BTL-785F and HPM-6000UF Devices for Women's Intimate Wellness
The goal of this clinical trial is to evaluate the combined application of BTL-785F and HPM-6000UF Devices in improving quality of life in women with negative changes in the urogenital system (vulvovaginal atrophy symptoms…
- Conditions
- Vulvovaginal Atrophy, Urinary Incontinence, Sexual Dysfunction
- Trial name
- NCT06846216
- Testing
- Treatment with BTL-785F and HPM-6000UF Devices
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Neurodegenerative Diseases, Osteoarthritis
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF).
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases
- Trial name
- NCT01953523
- Testing
- Administration of autologous adipose derived SVF
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Elliot Lander
Obstetric Labour, Premature, Premature Ejaculation
A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects
PreTerm Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the body during labor.
- Trial name
- NCT00449709
- Testing
- GSK221149
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Autoimmune Diseases, Cardiovascular Disorders
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions.
- Conditions
- Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease
- Trial name
- NCT04684602
- Testing
- PrimePro™/ PrimeMSK™
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
Psoriatic Arthritis
The Effect of Psoriatic Arthritis on Female Sexual Dysfunction
Psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.
- Trial name
- NCT06370221
- Testing
- The effect of psoriatic Arthritis
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Dysmenorrhea, Dyspareunia
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in…
- Conditions
- Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
- Trial name
- NCT00318500
- Testing
- ERB-041
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02338960)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 714 people
- Sponsor
- Palatin Technologies, Inc
Pelvic Organ Prolapse
Restorelle® Mesh Versus Native Tissue Repair for Prolapse
The purpose of this study is to collect information on the safety and effectiveness of Restorelle Direct Fix mesh and the surgical procedure to implant Restorelle.
- Trial name
- NCT02162615
- Testing
- Restorelle Direct Fix A, Restorelle Direct Fix P, Native Tissue Repair Anterior
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 810 people
- Sponsor
- Coloplast A/S
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness
This is a pilot study, assessing the ability and safety of the use of VR101 intravaginal ring to relieve the symptoms of vaginal dryness, in peri and post-menopausal women. VR1010 is designed to release glycerol.
- Trial name
- NCT02029053
- Testing
- Vaginal Lubrication Ring for Vaginal Dryness
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- J3 Bioscience, Inc.
Sexual Dysfunction, Physiological
Efficacy of VR101 as a Personal Lubricant
This Clinical Investigation (CI03) is designed to validate the efficacy of the VR101 lubricating Intravaginal Ring (IVR) as a personal lubricant device.
- Trial name
- NCT04288752
- Testing
- VR101 Lubricating Intravaginal Ring
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- J3 Bioscience, Inc.
Female Sexual Arousal Disorder, Female Sexual Dysfunction
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.
- Trial name
- NCT06116045
- Testing
- BZ371A 7.5 mg (1.5 ml), BZ371A 5.0 mg (1.0 ml), BZ371A 2.5 mg (0.5 ml)
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
Menopause
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal…
- Trial name
- NCT00196378
- Testing
- Synthetic Conjugated estrogens, B
- Where
- 38 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duramed Research
Endometriosis
Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03992846
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 486 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Vaginismus, Vaginal Atrophy
Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women
Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
- Conditions
- Vaginismus, Vaginal Atrophy, Menopause
- Trial name
- NCT06564883
- Testing
- 0.20% sodium hyaluronate gel
- Volunteers
- 45 people
- Sponsor
- Biolab Sanus Farmaceutica
Female Sexual Arousal Disorder
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil…
- Trial name
- RESPOND (NCT04948151)
- Testing
- Sildenafil
- Where
- 51 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Strategic Science & Technologies, LLC